Search Results

Dylan Scott Eiger, Chloe Hicks,  Dr.

January 2022 "Voltaire argued, “Perfection is attained by slow degrees; it requires the hand of time.” However, in drug discovery projects, perfection can’t be attained soon enough. A project to develop a perfect drug, or a drug that is as safe and effective as possible, may never begin if it can’t be completed quickly. Such predicaments must have been familiar to the philosopher. After all, he also complained that the perfect is the enemy of the good. If only Voltaire were here today to see how drug discovery is being accelerated by new technologies. He might reverse himself and declare that the perfect can in fact be the friend of the good. Several new technologies that are being used to accelerate drug discovery are highlighted in this article. They include small molecules that conditionally modulate proteins in their functional state; three-dimensional (3D) cell models, or organoid models, that assist with target identification, high-throughput drug screening, drug efficacy analyses, and toxicity studies; technologies that stabilize G protein–coupled receptors (GPCRs) to enable the discovery of agonistic biologics; and automated instrumentation that enables the overnight synthesis of mRNA." Read more at the source #DrGPCR #GPCR #IndustryNews

part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick

Ep 111 with Chloe Hicks Dr. GPCR Podcast << Back to podcast list Chloe Hicks About Chloe Hicks Chloe Hicks will graduate from Duke Chloe Hicks on the web ORCID LinkedIn Dr.

GPCR Podcast << Back to podcast list Jacob Lee & Jin Choe About this episode In this special episode Jacob Lee and Jin Choe met in ninth grade in English class and have been friends since. GPCR Ecosystem Jin Choe on LinkedIn Jin Choe on Dr.

Nicholas Holliday After an undergraduate degree at the University of Cambridge, Nick carried out his It was these studies and subsequent postdoctoral work that led to Nick's interest in peptide messengers Nick joined the University of Nottingham in 2006, where he is now Associate Professor, establishing a Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief